Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone liposome + azacitidine
- Development stage
- Unknown
- Lead developer
- CSPC Zhongnuo Pharmaceutical
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
Mitoxantrone liposome + azacitidine is an investigational combination therapy consisting of a liposomal formulation of mitoxantrone (Lipo-MIT) and the hypomethylating agent azacitidine. Mitoxantrone is a synthetic anthracenedione that intercalates into DNA, inhibiting topoisomerase II and leading to DNA strand breaks and apoptosis in rapidly dividing cells. The liposomal formulation (Lipo-MIT) enhances drug delivery, prolongs circulation time, and reduces off-target toxicity compared to conventional mitoxantrone. Azacitidine is a nucleoside analog that incorporates into DNA and RNA, inhibiting DNA methyltransferase, resulting in hypomethylation of DNA and reactivation of tumor suppressor genes. This combination has been studied primarily for relapsed/refractory hematologic malignancies such as angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma (PTCL), acute myeloid leukemia (AML), with the aim to improve efficacy while maintaining manageable toxicity profiles[4][5][6].
- Brand names
- Duoenda
- Other names
- mitoxantrone hydrochloride liposome + azacitidineLipo-MIT + azacitidine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone liposome + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone liposome + azacitidine.